Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report.

Khan AB, Shah A, Ahmad S, Khan MI, Amir A

Cureus6 May 2023Cited by 4 (Europe PMC)

PMID37284401PMCIDPMC10241188DOI10.7759/cureus.38630PepBankPUB-37284401

Summary

The article discusses the use of dulaglutide (Trulicity) in treating type 2 diabetes mellitus. Dulaglutide is a synthetic analog of glucagon-like peptide (GLP-1) that binds to GLP-1 receptors, enhancing insulin secretion and reducing postprandial glucagon and food intake. Dulaglutide has a longer half-life than GLP-1, making it more clinically useful. The recommended dosage of dulaglutide is 0.75 mg/0.5 mL subcutaneously once weekly, which can be increased as needed for adequate glycemic control. We describe a case of acute pancreatitis in a 37-year-old male with a past medical history of type 2 diabetes mellitus who was admitted for epigastric pain radiating to the back. Lipase level was elevated at 1508, and a computed tomography (CT) scan of the abdomen showed fat stranding around the pancreas consistent with pancreatitis. The patient was on dulaglutide (Trulicity) at 0.75 mg q. weekly for about two years; this dose was increased to 1.5 mg q. weekly two months ago. He developed symptoms of abdominal pain, nausea, and vomiting after receiving the last dose of Trulicity, which was two weeks before he presented to the emergency department as a cause of acute pancreatitis. Dulaglutide use has been known to cause a mild elevation of pancreatic enzyme levels; there have been few reported cases of dulaglutide-associated acute pancreatitis in the literature. The case report highlights the adverse effects of dulaglutide in diabetic patients and the importance of monitoring pancreatic enzyme levels in patients taking dulaglutide.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanCase report or seriesSafety outcome
A man with diabetes developed acute pancreatitis during dulaglutide treatment after dose escalation.
In plain wordsOne man developed acute pancreatitis during dulaglutide treatment after a dose increase.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableAcute pancreatitis
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.75 mg weekly increased to 1.5 mg weekly · About two years at 0.75 mg weekly, then two months at 1.5 mg weeklyAs given in this study (human).
Source sentences
Summary
We describe a case of acute pancreatitis in a 37-year-old male with a past medical history of type 2 diabetes mellitus who was admitted for epigastric pain radiating to the back. Lipase level was elevated at 1508, and a computed tomography (CT) scan of the abdomen showed fat stranding around the pancreas consistent with pancreatitis.
2 context sentences(design, population, supporting numbers)
Summary · context
We describe a case of acute pancreatitis in a 37-year-old male with a past medical history of type 2 diabetes mellitus who was admitted for epigastric pain radiating to the back.
Summary · context
The patient was on dulaglutide (Trulicity) at 0.75 mg q. weekly for about two years; this dose was increased to 1.5 mg q. weekly two months ago.
Show in the study text Report a problemFND-3728440101
02HumanCase report or seriesSafety outcome
A man with pancreatitis during dulaglutide treatment had a lipase level of 1508.
In plain wordsOne man with pancreatitis during dulaglutide treatment had elevated lipase.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseElevated lipase
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.75 mg weekly increased to 1.5 mg weekly · About two years at 0.75 mg weekly, then two months at 1.5 mg weeklyAs given in this study (human).
Measurements
Lipase
1508
At presentation
Source sentences
Summary
Lipase level was elevated at 1508, and a computed tomography (CT) scan of the abdomen showed fat stranding around the pancreas consistent with pancreatitis.
2 context sentences(design, population, supporting numbers)
Summary · context
We describe a case of acute pancreatitis in a 37-year-old male with a past medical history of type 2 diabetes mellitus who was admitted for epigastric pain radiating to the back.
Summary · context
The patient was on dulaglutide (Trulicity) at 0.75 mg q. weekly for about two years; this dose was increased to 1.5 mg q. weekly two months ago.
Show in the study text Report a problemFND-3728440102
03HumanCase report or seriesSafety outcome
A man with diabetes developed abdominal pain after his last dulaglutide dose.
In plain wordsOne man developed abdominal pain after his last dulaglutide dose.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableAbdominal pain
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.75 mg weekly increased to 1.5 mg weekly · About two years at 0.75 mg weekly, then two months at 1.5 mg weeklyAs given in this study (human).
Source sentences
Summary
He developed symptoms of abdominal pain, nausea, and vomiting after receiving the last dose of Trulicity, which was two weeks before he presented to the emergency department as a cause of acute pancreatitis.
2 context sentences(design, population, supporting numbers)
Summary · context
We describe a case of acute pancreatitis in a 37-year-old male with a past medical history of type 2 diabetes mellitus who was admitted for epigastric pain radiating to the back.
Summary · context
The patient was on dulaglutide (Trulicity) at 0.75 mg q. weekly for about two years; this dose was increased to 1.5 mg q. weekly two months ago.
Show in the study text Report a problemFND-3728440103
04HumanCase report or seriesSafety outcome
A man with diabetes developed nausea after his last dulaglutide dose.
In plain wordsOne man developed nausea after his last dulaglutide dose.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableNausea
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.75 mg weekly increased to 1.5 mg weekly · About two years at 0.75 mg weekly, then two months at 1.5 mg weeklyAs given in this study (human).
Source sentences
Summary
He developed symptoms of abdominal pain, nausea, and vomiting after receiving the last dose of Trulicity, which was two weeks before he presented to the emergency department as a cause of acute pancreatitis.
2 context sentences(design, population, supporting numbers)
Summary · context
We describe a case of acute pancreatitis in a 37-year-old male with a past medical history of type 2 diabetes mellitus who was admitted for epigastric pain radiating to the back.
Summary · context
The patient was on dulaglutide (Trulicity) at 0.75 mg q. weekly for about two years; this dose was increased to 1.5 mg q. weekly two months ago.
Show in the study text Report a problemFND-3728440104
05HumanCase report or seriesSafety outcome
A man with diabetes developed vomiting after his last dulaglutide dose.
In plain wordsOne man developed vomiting after his last dulaglutide dose.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableVomiting
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.75 mg weekly increased to 1.5 mg weekly · About two years at 0.75 mg weekly, then two months at 1.5 mg weeklyAs given in this study (human).
Source sentences
Summary
He developed symptoms of abdominal pain, nausea, and vomiting after receiving the last dose of Trulicity, which was two weeks before he presented to the emergency department as a cause of acute pancreatitis.
2 context sentences(design, population, supporting numbers)
Summary · context
We describe a case of acute pancreatitis in a 37-year-old male with a past medical history of type 2 diabetes mellitus who was admitted for epigastric pain radiating to the back.
Summary · context
The patient was on dulaglutide (Trulicity) at 0.75 mg q. weekly for about two years; this dose was increased to 1.5 mg q. weekly two months ago.
Show in the study text Report a problemFND-3728440105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.